

**PRESS RELEASE**

30 June 2023 10:12:00 CEST

## **Senzime granted European patent for TetraSens**

Uppsala, Sweden, June 30, 2023. Senzime AB (publ), a leader in the field of peri- and post-operative patient monitoring solutions, today announced today that the European Patent Office (EPO) has issued a Decision to Grant the patent application for the TetraSens disposable sensor.

TetraSens is an advanced disposable sensor based on a unique design with electrodes that stimulate the peripheral nerve and directly measure the evoked electromyographic (EMG) response of the muscle. This provides a precise and automatic measurement of the muscle's response to stimulus.

TetraSens is already protected by a US patent and is used together with Senzime's TetraGraph monitor to accurately monitor a patient's neuromuscular function during and after surgery. With the new patent, Senzime has a patent portfolio of a total of 89 patents.

"Senzime drives strategic innovation based on the mission of eliminating complications related to anesthesia. The new patent for TetraSens strengthens our competitive edge and is further proof of our leading position in algorithm-based patient monitoring," commented Anders Jacobson, Chief Innovation Officer at Senzime.

**For further information, please contact:**

---

Philip Siberg, CEO of Senzime AB  
Phone: +46 (0) 707 90 67 34, e-mail: [philip.siberg@senzime.com](mailto:philip.siberg@senzime.com)

**About Senzime**

---

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at [senzime.com](https://senzime.com).

## Image Attachments

---

TetraGraph and TetraSens

Attachments

---

Senzime granted European patent for TetraSens